You just read:

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

News provided by

Infinity Pharmaceuticals, Inc.

19 May, 2016, 08:00 ET